Grau Maria V, Baron John A, Sandler Robert S, Wallace Kristin, Haile Robert W, Church Timothy R, Beck Gerald J, Summers Robert W, Barry Elizabeth L, Cole Bernard F, Snover Dale C, Rothstein Richard, Mandel Jack S
Department of Community and Family Medicine, Dartmouth Medical School, Lebanon, NH, USA.
J Natl Cancer Inst. 2007 Jan 17;99(2):129-36. doi: 10.1093/jnci/djk016.
Calcium supplementation has been shown to decrease the risk of recurrence of colorectal adenomas in randomized trials. However, the duration of this protective effect after cessation of active supplementation is not known.
In the Calcium Polyp Prevention Study, 930 subjects with a previous colorectal adenoma were randomly assigned from November 1988 through April 1992 to receive placebo or 1200 mg of elemental calcium daily for 4 years. The Calcium Follow-up Study was an observational phase of the trial that tracked adenoma occurrence for an average of 7 years after the end of randomized treatment and gathered information regarding the use of medications, vitamins, and supplements during that time. We obtained follow-up information for 822 subjects, 597 of whom underwent at least one colonoscopy after the end of study treatment and are included in this analysis. Generalized linear models were used to compute relative risks (RRs) and 95% confidence intervals (CIs) for the effect of randomized calcium treatment on risk of adenoma recurrence during the first 5 years after study treatment ended and during the subsequent 5 years. Statistical tests were two-sided.
During the first 5 years after randomized treatment ended, subjects in the calcium group still had a substantially and statistically significantly lower risk of any adenoma than those in the placebo group (31.5% versus 43.2%; adjusted RR = 0.63, 95% CI = 0.46 to 0.87, P = .005) and a smaller and not statistically significant reduction in risk of advanced adenomas (adjusted RR = 0.85, 95% CI = 0.43 to 1.69, P = .65). However, the randomized treatment was not associated with the risk of any type of polyp during the next 5 years. The findings were broadly similar when the analysis was restricted to subjects who did not report use of any calcium supplements after the treatment phase of the trial ended.
The protective effect of calcium supplementation on risk of colorectal adenoma recurrence extends up to 5 years after cessation of active treatment, even in the absence of continued supplementation.
在随机试验中,补充钙已被证明可降低结直肠腺瘤复发风险。然而,停止积极补充后这种保护作用的持续时间尚不清楚。
在钙息肉预防研究中,从1988年11月至1992年4月,将930名既往有结直肠腺瘤的受试者随机分配,分别接受安慰剂或每日1200毫克元素钙,为期4年。钙随访研究是该试验的一个观察阶段,在随机治疗结束后平均追踪腺瘤发生情况7年,并收集该期间有关药物、维生素和补充剂使用的信息。我们获得了822名受试者的随访信息,其中597名在研究治疗结束后至少接受了一次结肠镜检查,并纳入本分析。使用广义线性模型计算随机钙治疗对研究治疗结束后前5年和随后5年腺瘤复发风险的影响的相对风险(RRs)和95%置信区间(CIs)。统计检验为双侧检验。
在随机治疗结束后的前5年,钙组受试者发生任何腺瘤的风险仍显著低于安慰剂组(31.5%对43.2%;校正RR = 0.63,95% CI = 0.46至0.87,P = 0.005),而高级别腺瘤风险降低幅度较小且无统计学意义(校正RR = 0.85,95% CI = 0.43至1.69,P = 0.65)。然而,在接下来的5年中,随机治疗与任何类型息肉的风险无关。当分析仅限于试验治疗阶段结束后未报告使用任何钙补充剂的受试者时,结果大致相似。
补充钙对结直肠腺瘤复发风险的保护作用在停止积极治疗后可持续长达5年,即使在没有持续补充的情况下也是如此。